Prosecution Insights
Prosecution Insights
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (80%) |
| §112 only | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BELYAVSKYI, MICHAIL A | 1 | 63.8% | +27.5% |
| RAVINDRA, KRISHNA NUGGEHALLI | 1 | 72.7% | +3.6% |
| ROGERS, ERIC JASON | 1 | 59.2% | +28.6% |
| VIGIL, TORIANA NICHOLE | 1 | 53.2% | +21.4% |
| WANG, CHANG YU | 1 | 33.6% | +53.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17637113 | AQUEOUS PHARMACEUTICAL COMPOSITION OF ANTI-PD1 ANTIBODY PROLGOLIMAB AND USE THEREOF | VIGIL, TORIANA NICHOLE | 50d overdue |
| 17296597 | DNA cutting means based on Cas9 protein from biotechnologically significant bacterium Clostridium cellulolyticum | WANG, CHANG YU | 49d overdue |
| 17998567 | AQUEOUS PHARMACEUTICAL COMPOSITION OF LEVILIMAB | BELYAVSKYI, MICHAIL A | 15d |
| 17761838 | IMMUNOCYTOKINE COMPRISING HETERODYMERIC PROTEIN COMPLEX BASED ON IL-15/IL-15RA | ROGERS, ERIC JASON | 70d |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| 1636 | 1 |
| 1638 | 1 |
| 1612 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17998567 | AQUEOUS PHARMACEUTICAL COMPOSITION OF LEVILIMAB | BELYAVSKYI, MICHAIL A | 1644 | §103 | Final Rejection | 15d | Pending | Nov 11, 2022 |
| 17775626 | USE OF CAS9 PROTEIN FROM THE BACTERIUM PASTEURELLA PNEUMOTROPICA | RAVINDRA, KRISHNA NUGGEHALLI | 1636 | §103 | Final Rejection | 15d | Pending | May 10, 2022 |
| 17761838 | IMMUNOCYTOKINE COMPRISING HETERODYMERIC PROTEIN COMPLEX BASED ON IL-15/IL-15RA | ROGERS, ERIC JASON | 1638 | §112 | Final Rejection | 70d | Pending | Mar 18, 2022 |
| 17637113 | AQUEOUS PHARMACEUTICAL COMPOSITION OF ANTI-PD1 ANTIBODY PROLGOLIMAB AND USE THEREOF | VIGIL, TORIANA NICHOLE | 1612 | §103 | Final Rejection | 50d overdue | Pending | Feb 22, 2022 |
| 17296597 | DNA cutting means based on Cas9 protein from biotechnologically significant bacterium Clostridium cellulolyticum | WANG, CHANG YU | 1675 | §103 | Final Rejection | 49d overdue | Pending | May 25, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial